Onyinyechi Vivian Uhuo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Onyinyechi Vivian Uhuo has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Emmanuel Iheanyichukwu Iwuoha
SensorLab (University of the Western Cape Sensor Laboratories) 4th Floor Chemical Sciences Building University of the Western Cape Bellville Cape Town South Africa
9 shared publications Marlon Oranzie
University of the Western Cape 4th Floor Chemical Sciences Building, Robert Sobukwe Road , Bellville
5 shared publications- Kaylin Cleo Januarie
SensorLab (University of the Western Cape Sensor Laboratories), Chemical Sciences Building, University of the Western Cape, Bellville, 7535, Cape Town, South Africa
4 shared publications Nelia Sanga
University of the Western Cape 4th Floor Chemical Sciences Building, Robert Sobukwe Road , Bellville
3 shared publications- Chinwe Oluchi Ikpo
Key Laboratory for NanoElectrochemistry, University of the Western Cape, 4th Floor Chemical Sciences Building, Robert Sobukwe Road, Bellville 7535, Cape Town, South Africa
2 shared publications - Jaymi January
University of the Western Cape 4th Floor Chemical Sciences Building, Robert Sobukwe Road , Bellville
2 shared publications
Latest Publications
- Open Access
- 22 July 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (30) , 21947-21980
Advances on Sensors and Diagnostics of SARS-CoV-2 Biomarkers
- 22 July 2026
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 98 (30) , 21947-21980
Open AccessAdvances on Sensors and Diagnostics of SARS-CoV-2 Biomarkers
- Open Access
- 16 July 2025
- Published by Elsevier in Electrochimica Acta
- Vol. 538
Trimetallic chalcogenide-sensitised interferon gamma aptasensor for tuberculosis
- 16 July 2025
- Published by Elsevier in Electrochimica Acta
- Vol. 538
Open AccessTrimetallic chalcogenide-sensitised interferon gamma aptasensor for tuberculosis
- 8 December 2024
- Published by Elsevier in Next Research
- Vol. 2 (1)
A novel LiSmZrO3 perovskite-amplified interferon gamma-sensitive electrochemical tuberculosis aptasensor
- 8 December 2024
- Published by Elsevier in Next Research
- Vol. 2 (1)
A novel LiSmZrO3 perovskite-amplified interferon gamma-sensitive electrochemical tuberculosis aptasensor
- Open Access
- 24 June 2024
- Published by Wiley in ChemElectroChem
- Vol. 11 (14)
Chronocoulometric Quantum Dot Aptasensor for SARS‐CoV‐2 Nucleocapsid Protein Biomarker
For the first time, a novel mercaptosuccinic acid‐capped tungsten telluride quantum dot (MSA‐WTe3‐QD)‐based electrochemical aptasensor was designed for the determination of SARS‐CoV‐2 N‐protein in synthetic human serum, plasma and urine. The MSA‐WTe3‐QD which exhibited spherical morphology and an average diameter of 3.56 nm were synthesized through a bottom‐up approach. The aptasensor was prepared by firstly immobilizing MSA‐WTe3‐QD on a screen‐printed carbon electrode (SPCE) by using the 1‐ethyl‐3‐(3‐dimethylaminopropyl)carbodiimide/N‐hydroxysuccinimide (EDC/NHS) coupling chemistry. Thereafter, amine‐terminated 90‐mer ssDNA aptamer was deposited on the modified SPCE and left to cure to form the aptasensor. Using the chronocoulometry signal transduction technique, the aptasensor's calibration with N‐protein gave a linear range value of 1–9 pg.mL−1 and a limit of detection (LOD) value of 0.08 pg.mL−1. The LOD value of the aptasensor was 8 times lower than the LOD value of 0.71 pg.mL−1 obtained with a commercial N‐protein ELISA kit. When tested in simulated real samples the aptasensor recovery rates of 95–103.33 % were obtained. In the presence of various interferents, the aptasensor displayed good selectivity to N‐protein.
- 24 June 2024
- Published by Wiley in ChemElectroChem
- Vol. 11 (14)
Open AccessChronocoulometric Quantum Dot Aptasensor for SARS‐CoV‐2 Nucleocapsid Protein Biomarker
For the first time, a novel mercaptosuccinic acid‐capped tungsten telluride quantum dot (MSA‐WTe3‐QD)‐based electrochemical aptasensor was designed for the determination of SARS‐CoV‐2 N‐protein in synthetic human serum, plasma and urine. The MSA‐WTe3‐QD which exhibited spherical morphology and an average diameter of 3.56 nm were synthesized through a bottom‐up approach. The aptasensor was prepared by firstly immobilizing MSA‐WTe3‐QD on a screen‐printed carbon electrode (SPCE) by using the 1‐ethyl‐3‐(3‐dimethylaminopropyl)carbodiimide/N‐hydroxysuccinimide (EDC/NHS) coupling chemistry. Thereafter, amine‐terminated 90‐mer ssDNA aptamer was deposited on the modified SPCE and left to cure to form the aptasensor. Using the chronocoulometry signal transduction technique, the aptasensor's calibration with N‐protein gave a linear range value of 1–9 pg.mL−1 and a limit of detection (LOD) value of 0.08 pg.mL−1. The LOD value of the aptasensor was 8 times lower than the LOD value of 0.71 pg.mL−1 obtained with a commercial N‐protein ELISA kit. When tested in simulated real samples the aptasensor recovery rates of 95–103.33 % were obtained. In the presence of various interferents, the aptasensor displayed good selectivity to N‐protein.
- Open Access
- 18 March 2024
- Published by Elsevier in Bioelectrochemistry
- Vol. 158, 108693
Interferon gamma (IFN-γ)-sensitive TB aptasensor based on novel chitosan-indium nano-kesterite (χtCITS)-labeled DNA aptamer hairpin technology
- 18 March 2024
- Published by Elsevier in Bioelectrochemistry
- Vol. 158, 108693
Open AccessInterferon gamma (IFN-γ)-sensitive TB aptasensor based on novel chitosan-indium nano-kesterite (χtCITS)-labeled DNA aptamer hairpin technology
- 9 January 2023
- Published by Elsevier in Electrochimica Acta
- Vol. 441
Nanostructured europium-doped layered lithium manganese oxide as a prospective cathode material for aqueous lithium-ion battery
- 9 January 2023
- Published by Elsevier in Electrochimica Acta
- Vol. 441
Nanostructured europium-doped layered lithium manganese oxide as a prospective cathode material for aqueous lithium-ion battery
- Open Access
- 25 November 2022
- Published by Elsevier in Journal of Alloys and Compounds
- Vol. 935, 168211
Novel heterojunction superstrate Cu2ZnInS4−x (CZIS) thin film kesterite solar cell with vertical arrays of hexagonal ZnO nanorods window layer
- 25 November 2022
- Published by Elsevier in Journal of Alloys and Compounds
- Vol. 935, 168211
Open AccessNovel heterojunction superstrate Cu2ZnInS4−x (CZIS) thin film kesterite solar cell with vertical arrays of hexagonal ZnO nanorods window layer
- 15 September 2022
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 147 (21) , 4829-4837
Chronocoulometric signalling of BNP using a novel quantum dot aptasensor
This study is a first-time report of the development of a mercaptosuccinic acid-nickel selenide quantum dots (MSA-NiSe2 QDs)-based electrochemical aptasensor for brain natriuretic peptide (BNP) detection. Herein, novel MSA-NiSe2 QDs were synthesized by microwave irradiation. Microscopic and structural analysis revealed that the QDs are spherical with an average diameter of 2 nm. In the presence of the as-prepared QDs, an amine-modified DNA aptamer sequence was attached to a disposable sensing interface through 1-ethyl-3-(3-dimenthylaminopropyl) carbodiimide/N-hydroxysuccinimide coupling chemistries. Electroanalytical analysis revealed that the developed QDs-based electrochemical aptasensor is highly selective towards BNP and successfully detected BNP in both physiological buffer and human plasma samples with detection limits of 5.45 pg mL−1 and 31.95 pg mL−1, respectively. Moreover, the results revealed a 3-fold enhancement in the loading capacity of the BNP aptamer in the presence of MSA-NiSe2 QDs. By taking advantage of the physical and electronic properties of the novel QDs these materials can be easily adapted to other diagnostic approaches.
- 15 September 2022
- Published by Royal Society of Chemistry (RSC) in The Analyst
- Vol. 147 (21) , 4829-4837
Chronocoulometric signalling of BNP using a novel quantum dot aptasensor
This study is a first-time report of the development of a mercaptosuccinic acid-nickel selenide quantum dots (MSA-NiSe2 QDs)-based electrochemical aptasensor for brain natriuretic peptide (BNP) detection. Herein, novel MSA-NiSe2 QDs were synthesized by microwave irradiation. Microscopic and structural analysis revealed that the QDs are spherical with an average diameter of 2 nm. In the presence of the as-prepared QDs, an amine-modified DNA aptamer sequence was attached to a disposable sensing interface through 1-ethyl-3-(3-dimenthylaminopropyl) carbodiimide/N-hydroxysuccinimide coupling chemistries. Electroanalytical analysis revealed that the developed QDs-based electrochemical aptasensor is highly selective towards BNP and successfully detected BNP in both physiological buffer and human plasma samples with detection limits of 5.45 pg mL−1 and 31.95 pg mL−1, respectively. Moreover, the results revealed a 3-fold enhancement in the loading capacity of the BNP aptamer in the presence of MSA-NiSe2 QDs. By taking advantage of the physical and electronic properties of the novel QDs these materials can be easily adapted to other diagnostic approaches.
- 30 August 2022
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1234, 340326
Bioanalytical methods encompassing label-free and labeled tuberculosis aptasensors: A review
- 30 August 2022
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1234, 340326
Bioanalytical methods encompassing label-free and labeled tuberculosis aptasensors: A review
- 19 October 2020
- Published by Wiley in Electroanalysis
- Vol. 32 (12) , 3075-3085
Metallodendrimer‐sensitised Cytochrome P450 3A4 Electrochemical Biosensor for TB Drugs
A cytochrome P450 3A4 (CYP3A4) based enzymatic biosensor was developed with the incorporation of a first‐generation copper polypropyleneimine (CuPPI) metallodendrimer for the detection of anti‐tuberculosis (anti‐TB) drugs. The development of an electrochemical phenotype biosensor for this purpose is still vital since it aids in the ongoing fight against TB by determining metabolic profile. This allows TB treatment to be tailored on an individual patient basis, minimise adverse drug reactions and improve quality of life in TB patients. This simple biosensor was constructed via physical adsorption of CuPPI onto a gold electrode with subsequent electrostatic attachment of CYP3A4. The biosensor was successful in detecting all four first line anti‐TB drugs i. e. isoniazid, ethambutol, pyrazinamide and rifampicin with limits of detection ranging from 0.02244 to 0.1072 nM in 0.1 M phosphate buffer. The developed biosensor was then applied towards “real samples” in the form of spiked synthetic urine and plasma. Calibration curves were carried out in the complex matrices, which were diluted with 0.1 M PB. These yielded good LOD in the range of ultra‐low micromolar concentration i. e. 0.165–0.884 μM across all drugs. Recovery studies were also successful when detecting the real tablets in both plasma and urine with results ranging from 91.5 % to 108.5 %.
- 19 October 2020
- Published by Wiley in Electroanalysis
- Vol. 32 (12) , 3075-3085
Metallodendrimer‐sensitised Cytochrome P450 3A4 Electrochemical Biosensor for TB Drugs
A cytochrome P450 3A4 (CYP3A4) based enzymatic biosensor was developed with the incorporation of a first‐generation copper polypropyleneimine (CuPPI) metallodendrimer for the detection of anti‐tuberculosis (anti‐TB) drugs. The development of an electrochemical phenotype biosensor for this purpose is still vital since it aids in the ongoing fight against TB by determining metabolic profile. This allows TB treatment to be tailored on an individual patient basis, minimise adverse drug reactions and improve quality of life in TB patients. This simple biosensor was constructed via physical adsorption of CuPPI onto a gold electrode with subsequent electrostatic attachment of CYP3A4. The biosensor was successful in detecting all four first line anti‐TB drugs i. e. isoniazid, ethambutol, pyrazinamide and rifampicin with limits of detection ranging from 0.02244 to 0.1072 nM in 0.1 M phosphate buffer. The developed biosensor was then applied towards “real samples” in the form of spiked synthetic urine and plasma. Calibration curves were carried out in the complex matrices, which were diluted with 0.1 M PB. These yielded good LOD in the range of ultra‐low micromolar concentration i. e. 0.165–0.884 μM across all drugs. Recovery studies were also successful when detecting the real tablets in both plasma and urine with results ranging from 91.5 % to 108.5 %.